Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. cytologically or histologically confirmed primary NSCLC;~2. Stage IV primary NSCLC according to the International Association for the Study of Lung Cancer (IASLC) TNM Eighth Edition;~3. There must be at least one evaluable lesion judged according to RECIST1.1;~4. No sensitive mutation in EGFR and negative ALK rearrangement;~5. ≥18 years old;~6. The Eastern Cooperative Oncology Group (ECOG) physical status score was 0-2;~7. Life expectancy of more than 3 months;~8. Bone marrow and organs (liver and kidney) function well, which can meet the conventional conditions for chemotherapy: neutrophil count ≥1.5×109/ L, platelet count ≥75×109/ L, hemoglobin ≥9g/ dL, total bilirubin ≤1.5×ULN, transaminase ≤2.5×ULN, serum creatinine ≤1.5×ULN or creatinine clearance ≥45ml/min. (ULN: upper limit of normal value);~9. For female subjects of reproductive age, urine or serum pregnancy test should be negative within 7 days prior to receiving the first study drug administration (cycle 1, day 1).If a urine pregnancy test is not confirmed negative, a blood pregnancy test is required;For men, consent must be given to use appropriate methods of contraception or surgical sterilization during the trial and for 8 weeks after the last administration of the experimental drug;~10. Signing the informed consent;~11. Good compliance, follow-up, and voluntary compliance with relevant regulations of the study.-~Exclusion Criteria:~1. Small cell lung cancer;~2. Brain metastases with hemorrhage;~3. Currently participating in interventional clinical research and treatment;~4. Past anti-tumor immunotherapy with other anti-PD-1 /PD-L1 monoclonal antibodies;~5. Have received solid organ or blood system transplantation;~6. An active autoimmune disease requiring systemic treatment (e.g., use of palliative drugs, corticosteroids, or immunosuppressants) occurred within 2 years prior to initial administration.Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic;~7. having been diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first administration of the study;Physiological dose of glucocorticoids (≤10 mg/ day of prednisone or its equivalent) is allowed;~8. A history of non-infectious pneumonia requiring glucocorticoid therapy or current interstitial lung disease within 1 year prior to initial administration;~9. A known history of human immunodeficiency virus (HIV 1/2 antibody positive);~10. untreated active hepatitis B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- pharmacokinetic-guided pembrolizumab cohort (Type: EXPERIMENTAL): Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).